Harvard Bioscience (HBIO) Change in Receivables (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Change in Receivables data on file, last reported at -$1.4 million in Q1 2026.

• On a quarterly basis, Change in Receivables rose 2.23% year-over-year to -$1.4 million in Q1 2026; TTM through Mar 2026 was $966000.0, a 156.56% increase from a year earlier, with the FY2025 full-year figure at $934000.0, up 195.89% from the prior year.
• Change in Receivables for Q1 2026 stood at -$1.4 million, down from $4.0 million in the prior quarter.
• Over the last five years, Change in Receivables for HBIO reached as high as $4.0 million in Q4 2025 and fell as low as -$2.8 million in Q2 2024.
• Historically, Change in Receivables has averaged -$413882.4 across 5 years, with a median of -$855000.0 in 2023.
• Across the five-year window, Change in Receivables sank 897.32% in 2022 and surged 161.29% in 2023, its largest moves.
• Year by year, Change in Receivables stood at $1.3 million in 2022, then fell by 26.48% to $941000.0 in 2023, then jumped by 147.5% to $2.3 million in 2024, then surged by 69.86% to $4.0 million in 2025, then slumped by 135.54% to -$1.4 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were -$1.4 million in Q1 2026, $4.0 million in Q4 2025, and $210000.0 in Q3 2025.